These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 17395883)

  • 41. The effect of ABCG1 deficiency on atherosclerotic lesion development in LDL receptor knockout mice depends on the stage of atherogenesis.
    Meurs I; Lammers B; Zhao Y; Out R; Hildebrand RB; Hoekstra M; Van Berkel TJ; Van Eck M
    Atherosclerosis; 2012 Mar; 221(1):41-7. PubMed ID: 22196936
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Effects of High Fat Feeding and Diabetes on Regression of Atherosclerosis Induced by Low-Density Lipoprotein Receptor Gene Therapy in LDL Receptor-Deficient Mice.
    Willecke F; Yuan C; Oka K; Chan L; Hu Y; Barnhart S; Bornfeldt KE; Goldberg IJ; Fisher EA
    PLoS One; 2015; 10(6):e0128996. PubMed ID: 26046657
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Dihydromyricetin ameliorates atherosclerosis in LDL receptor deficient mice.
    Liu TT; Zeng Y; Tang K; Chen X; Zhang W; Xu XL
    Atherosclerosis; 2017 Jul; 262():39-50. PubMed ID: 28500865
    [TBL] [Abstract][Full Text] [Related]  

  • 44. SGLT2 inhibition reduces atherosclerosis by enhancing lipoprotein clearance in Ldlr
    Al-Sharea A; Murphy AJ; Huggins LA; Hu Y; Goldberg IJ; Nagareddy PR
    Atherosclerosis; 2018 Apr; 271():166-176. PubMed ID: 29518749
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Effect of streptozotocin-induced hyperglycemia on lipid profiles, formation of advanced glycation endproducts in lesions, and extent of atherosclerosis in LDL receptor-deficient mice.
    Reaven P; Merat S; Casanada F; Sutphin M; Palinski W
    Arterioscler Thromb Vasc Biol; 1997 Oct; 17(10):2250-6. PubMed ID: 9351397
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Troglitazone inhibits formation of early atherosclerotic lesions in diabetic and nondiabetic low density lipoprotein receptor-deficient mice.
    Collins AR; Meehan WP; Kintscher U; Jackson S; Wakino S; Noh G; Palinski W; Hsueh WA; Law RE
    Arterioscler Thromb Vasc Biol; 2001 Mar; 21(3):365-71. PubMed ID: 11231915
    [TBL] [Abstract][Full Text] [Related]  

  • 47. RAGE mediates oxidized LDL-induced pro-inflammatory effects and atherosclerosis in non-diabetic LDL receptor-deficient mice.
    Sun L; Ishida T; Yasuda T; Kojima Y; Honjo T; Yamamoto Y; Yamamoto H; Ishibashi S; Hirata K; Hayashi Y
    Cardiovasc Res; 2009 May; 82(2):371-81. PubMed ID: 19176597
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Deficiency of HIF1α in Antigen-Presenting Cells Aggravates Atherosclerosis and Type 1 T-Helper Cell Responses in Mice.
    Chaudhari SM; Sluimer JC; Koch M; Theelen TL; Manthey HD; Busch M; Caballero-Franco C; Vogel F; Cochain C; Pelisek J; Daemen MJ; Lutz MB; Görlach A; Kissler S; Hermanns HM; Zernecke A
    Arterioscler Thromb Vasc Biol; 2015 Nov; 35(11):2316-25. PubMed ID: 26404487
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Prevention of oxLDL uptake leads to decreased atherosclerosis in hematopoietic NPC1-deficient Ldlr
    Jeurissen MLJ; Walenbergh SMA; Houben T; Gijbels MJJ; Li J; Hendrikx T; Oligschlaeger Y; van Gorp PJ; Binder CJ; Donners MMPC; Shiri-Sverdlov R
    Atherosclerosis; 2016 Dec; 255():59-65. PubMed ID: 27816810
    [TBL] [Abstract][Full Text] [Related]  

  • 50. PKC-β activation inhibits IL-18-binding protein causing endothelial dysfunction and diabetic atherosclerosis.
    Durpès MC; Morin C; Paquin-Veillet J; Beland R; Paré M; Guimond MO; Rekhter M; King GL; Geraldes P
    Cardiovasc Res; 2015 May; 106(2):303-13. PubMed ID: 25808972
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Macrophage ABCG1 deletion disrupts lipid homeostasis in alveolar macrophages and moderately influences atherosclerotic lesion development in LDL receptor-deficient mice.
    Out R; Hoekstra M; Hildebrand RB; Kruit JK; Meurs I; Li Z; Kuipers F; Van Berkel TJ; Van Eck M
    Arterioscler Thromb Vasc Biol; 2006 Oct; 26(10):2295-300. PubMed ID: 16857950
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Human aldose reductase expression accelerates diabetic atherosclerosis in transgenic mice.
    Vikramadithyan RK; Hu Y; Noh HL; Liang CP; Hallam K; Tall AR; Ramasamy R; Goldberg IJ
    J Clin Invest; 2005 Sep; 115(9):2434-43. PubMed ID: 16127462
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Increased atherosclerosis in streptozotocin-induced diabetic mice.
    Kunjathoor VV; Wilson DL; LeBoeuf RC
    J Clin Invest; 1996 Apr; 97(7):1767-73. PubMed ID: 8601643
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Amelioration of Hyperglycemia with a Sodium-Glucose Cotransporter 2 Inhibitor Prevents Macrophage-Driven Atherosclerosis through Macrophage Foam Cell Formation Suppression in Type 1 and Type 2 Diabetic Mice.
    Terasaki M; Hiromura M; Mori Y; Kohashi K; Nagashima M; Kushima H; Watanabe T; Hirano T
    PLoS One; 2015; 10(11):e0143396. PubMed ID: 26606676
    [TBL] [Abstract][Full Text] [Related]  

  • 55. PPARalpha, but not PPARgamma, activators decrease macrophage-laden atherosclerotic lesions in a nondiabetic mouse model of mixed dyslipidemia.
    Hennuyer N; Tailleux A; Torpier G; Mezdour H; Fruchart JC; Staels B; Fiévet C
    Arterioscler Thromb Vasc Biol; 2005 Sep; 25(9):1897-902. PubMed ID: 15994444
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Deletion of Macrophage Low-Density Lipoprotein Receptor-Related Protein 1 (LRP1) Accelerates Atherosclerosis Regression and Increases C-C Chemokine Receptor Type 7 (CCR7) Expression in Plaque Macrophages.
    Mueller PA; Zhu L; Tavori H; Huynh K; Giunzioni I; Stafford JM; Linton MF; Fazio S
    Circulation; 2018 Oct; 138(17):1850-1863. PubMed ID: 29794082
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Monocytic MKP-1 is a Sensor of the Metabolic Environment and Regulates Function and Phenotypic Fate of Monocyte-Derived Macrophages in Atherosclerosis.
    Kim HS; Tavakoli S; Piefer LA; Nguyen HN; Asmis R
    Sci Rep; 2016 Sep; 6():34223. PubMed ID: 27670844
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Diabetic dyslipidemia.
    Kreisberg RA
    Am J Cardiol; 1998 Dec; 82(12A):67U-73U; discussion 85U-86U. PubMed ID: 9915665
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Deletion of Lymphangiogenic and Angiogenic Growth Factor VEGF-D Leads to Severe Hyperlipidemia and Delayed Clearance of Chylomicron Remnants.
    Tirronen A; Vuorio T; Kettunen S; Hokkanen K; Ramms B; Niskanen H; Laakso H; Kaikkonen MU; Jauhiainen M; Gordts PLSM; Ylä-Herttuala S
    Arterioscler Thromb Vasc Biol; 2018 Oct; 38(10):2327-2337. PubMed ID: 30354205
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Peroxisome proliferator-activated receptor δ agonist GW1516 attenuates diet-induced aortic inflammation, insulin resistance, and atherosclerosis in low-density lipoprotein receptor knockout mice.
    Bojic LA; Burke AC; Chhoker SS; Telford DE; Sutherland BG; Edwards JY; Sawyez CG; Tirona RG; Yin H; Pickering JG; Huff MW
    Arterioscler Thromb Vasc Biol; 2014 Jan; 34(1):52-60. PubMed ID: 24158519
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.